Extrapulmonary small cell carcinoma
arising in the prostate gland has been described in several case series and case reports.
Primary extrapulmonary small cell carcinoma
has been reported in a number of organs (3).
The prognosis for patients with extrapulmonary small cell carcinoma
is poor, as 5-year survival is only 13%.
The epidemiology and survival of extrapulmonary small cell carcinoma
in South East England, 1970-2004.
Clinical and therapeutic aspects of extrapulmonary small cell carcinoma
Cases of pulmonary small cell carcinoma, extrapulmonary small cell carcinoma
, and Merkel cell carcinoma were retrieved from the surgical pathology and consultation files of the Queen Elizabeth Hospital, Hong Kong, and the Ohio State University Medical Center, Columbus, Ohio.
Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas
but not in other extrapulmonary neuroendocrine tumors.
Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas
128) Although TTF-1 can be positive in 70% to 90% of SCLCs, (127, 139-143) a study showed that 7 of 16 extrapulmonary small cell carcinomas
(44%) were also positive for TTF-1.
Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas
and other neuroendocrine carcinomas of various primary sites.
Expression of TTF1 in extrapulmonary small cell carcinomas
was reported to be approximately 40%, 60%, 53%, 34%, 18%, 15%, respectively, in the bladder, prostate, GI tract, uterine cervix, colon, and salivary gland.